Our mission

To create an environment where the global biopharmaceutical industry can collaborate in order to accelerate their rate of progress, for the benefit of all. We do this by:

Bringing leaders together
to create future visions that focus the industry’s energy on the key emerging opportunities
Mobilizing communities
of the top experts around these opportunities, up and down the biopharma value chain
Creating partnerships
that enable change and provide the quickest route to implementation and results
Replacing isolation

with collaboration so that the industry shares, learns and
builds the best solutions together

What is BioPhorum?

Unique global collaboration
Powerful vehicle for change
Industry leaders and experts working in concert
Delivers results by pooling knowledge, practices and ideas


Industry changing initiatives

Member companies

Active participants

Thriving communities

Voice of the industry

Why BioPhorum?

We make the journey better, faster, cheaper …and results come in many ways

  • more effective compliance
  • better process control
  • lower business and supply chain continuity risk
  • lower waste
  • improved productivity
  • better investment decisions and costs avoided
  • faster approvals
  • faster batch release
  • accelerated improvement and technology adoption
  • faster capacity expansion
  • faster response
  • flexible operations supporting the product pipeline

Recent releases

biophorum post images website graphics cgt september special 160
Sep 20 2021

Using a matrix approach to address challenges for potency assay development for in vivo and ex vivo gene therapies.

The gene therapy field is advancing rapidly and though there has been significant progress, there are yet relatively few commercial products approved globally...
biophorum post images website graphics cgt september special4 158
Sep 20 2021

RNA: new CGT workstream to focus on this industry priority

When planning the 2021 BioPhorum Cell & Gene Therapy program, senior member representatives indicated that they wanted a new workstream focusing on what they...
biophorum post images website graphics cgt september special3 157
Sep 20 2021

Assessing EHS risks in CGT: a real-world example

In 2020, the Cell and Gene Therapy Phorum published an article Environmental Health and Biosafety Risk Assessment Guidance for Commercial-Scale Cell and Gene Therapy...
biophorum post images website graphics cgt september special2 159
Sep 18 2021

Illuminating the challenges of validating cell and gene therapies

The validation processes for general biologics and small molecule drugs are well established and there are many guidelines from regulatory agencies to provide...
biophorum post images website images september2 149
Sep 08 2021

Meeting the challenges in serialization to win in the battle against counterfeiting

The World Health Organization (WHO) estimates that medicine counterfeiting causes one million deaths a year and that 10% of all drugs sold globally are fake. Events...
biophorum post images website images september3 147
Sep 08 2021

How to create a toolbox to assess your high-risk HCPs

Host cell proteins (HCPs) are process-related impurities derived from host cells that may co-purify with a biopharmaceutical drug product.   The detection,...
Share This